Our mission
Every 3 seconds, someone somewhere in the world develops dementia. Today, more than 55 million people worldwide are living with dementia, and with the aging population, this number is expected to rise to 78 million by 2030 and 139 million by 2050. The World Health Organization therefore classifies dementia as a public health priority. Although dementia is still incurable, there have been significant developments in this field recently: disease-modifying drugs for the early stages of Alzheimer's disease have now been approved for the first time. We have made it our mission to enable early medical assessment and continuous monitoring of memory problems associated with Alzheimer's disease. That is why we have developed digital cognitive tests that are embedded in smartphone apps and can be used in research or healthcare.
To strengthen our Science & Innovation team, we are looking for a working student (f/x/m) who supports our vision and helps us coordinate our study projects. Ideally, you will be available to our team on a part-time basis (10-20 hours per week) starting March 1, 2026. You will receive compensation of €15 per hour.
Your point of contact
We look forward to receiving your documents, consisting of a cover letter and curriculum vitae in tabular form, to our People & Culture Team. We will also be happy to answer your questions in the first contact via e-mail (jobs@neotiv.com) or telephone!
About us
neotiv is a team of currently about 30 people: Scientists, developers and technically enthusiastic people who share a common vision of a better prevention of dementia. We develop digital solutions for the early detection and monitoring of memory problems.
neotiv is a spin-off from Otto-von-Guericke-University Magdeburg in close cooperation with the German Centre for Neurodegenerative Diseases (DZNE). Our team is passionate about shaping the future of medical care with digital tools and advancing dementia research. We work in Magdeburg, Berlin and across Germany and Europe. We are funded by renowned investors and science transfer funds that enable us to realize our mission of improving people's lives.